(TEVA) Teva Pharmaceutical Industries Active on the Generics Front

Teva Pharmaceutical Industries Ltd. (TEVA) has been pretty active on the generic product launch front with the company launching several generic products in the last few weeks. Among recently launched generic products are Teva’s generic versions of Sanofi’s (SNY) high blood pressure drugs, Avapro and Avalide, AstraZeneca’s (AZN) schizophrenia treatment, Seroquel, and Forest Laboratories’ (FRX) Lexapro.

While Teva will enjoy a 180-day period of marketing exclusivity where the generic launches of Avapro, Avalide and Lexapro are concerned, we note that other generic players like Dr. Reddy’s Laboratories (RDY) and Mylan (MYL) have also launched their generic versions of Seroquel.

As per IMS data, annual US sales of Avapro, Avalide, Seroquel, and Lexapro were $464 million, $124 million, $4.6 billion and $2.9 billion, respectively.

Teva also launched its authorized generic of version of Provigil. The branded product is marketed by Teva’s subsidiary, Cephalon, Inc. As per IMS data, Provigil’s annual sales were $1.1 billion in the US.

US Generics Picking Up

Teva’s US generics business, which had been performing below expectations in the past few quarters, showed signs of reviving during the fourth quarter of 2011 with sales benefiting from the exclusive generic launch of Eli Lilly’s (LLY) Zyprexa. Teva has partnered with Dr. Reddy’s Laboratories for Zyprexa.

Another important product launch was that of a generic version of Pfizer’s (PFE) Lipitor. Teva has an agreement with Ranbaxy regarding generic Lipitor.

The performance of the US generics segment should continue improving – the company expects $650 million in new launches in 2012. The company is guiding towards US generics segment sales of $5 billion, with sales slated to benefit from patents expiring and product launches. However, competition in the generics market will be tough.

We currently have a Neutral recommendation on Teva, which carries a Zacks #3 Rank (short-term ‘’Hold’’ rating).

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

FOREST LABS A (FRX): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

MYLAN INC (MYL): Free Stock Analysis Report

PFIZER INC (PFE): Free Stock Analysis Report

DOCTOR REDDYS (RDY): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

TEVA PHARM ADR (TEVA): Free Stock Analysis Report

View original at: Zacks Investment Research – All Commentary Articles

About vitalstocks

This is a sample profile field. Vitalstocks is the operating company for Stockbloghub. This will place the picture of the author or company in the profile. Here is another extra line of information.


Powered by Facebook Comments

Similar Posts: | | | | | | | | | | | | | | | | Drug Manufacturers - Other | Healthcare

RSS feeds: AstraZeneca plc | AZN | Dr. Reddy's Laboratories Limited | Eli Lilly & Company | Forest Laboratories Inc. | FRX | LLY | MYL | Mylan Inc. | PFE | Pfizer Inc. | RDY | Sanofi-Aventis | SNY | TEVA | Teva Pharmaceutical Industries Limited | Drug Manufacturers - Other | Healthcare |

Other Posts by | RSS Feed for this author